Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization

Phase 2

• Conditions: Chronic Limb Ischemia
• Interventions: Drug: Dexamethasone sodium phosphate injection, USP, 4 mg/mL

• Registration Number: NCT02479555
• Lead Sponsor: Mercator MedSystems, Inc.

Brief Summary

This is a prospective, multi-center, randomized pilot study to document the effects of adventitial delivery of dexamethasone after balloon angioplasty of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).

Detailed Description

This is a prospective, multi-center, randomized pilot study to document the effects of adventitial delivery of dexamethasone sodium phosphate injection (4 mg/mL) after balloon angioplasty of lesions below the knee in symptomatic patients with critical limb ischemia (CLI). Up to 120 patients (60 treatment and 60 control), including up to 20 Rutherford 6 patients (10 treatment and 10 control) at up to 30 sites in Europe and the United States. This study will assess the safety and effectiveness of Bullfrog Micro-Infusion Device adventitial deposition of dexamethasone in reducing inflammation and restenosis in patients with clinical evidence of chronic critical limb ischemia with an angiographically significant lesion in the infrapopliteal crural vessels.

Study Timeline

• Study First Submitted: 2015-06-15
• Study First Submitted QC: 2015-06-19
• Study First Posted: 2015-06-24
• Study Start: 2016-01
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-19
• Last Update Posted: 2020-02-20
• Primary Completion: 2020-08
• Study Completion: 2020-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Screening Criteria:

• Age ≥18 years
• Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an IRB/EC approved consent form
• Female patients of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation
• Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb from the popliteal artery to the ankle joint prior to the study procedure with Rutherford Category 4, 5 or 6
• Life expectancy >1 year in the Investigator's opinion

Angiographic Criteria:

• Successful revascularization of the TL with less than 30% residual stenosis, run-off down to the foot and direct in-line flow to any foot wound
• Reference vessel(s) diameter ≥2 mm
• Single or multiple atherosclerotic lesion ≥70% in at least one infrapopliteal crural target vessel including the tibioperoneal trunk that totals up to 30 cm in length (with no greater than 5 cm length of contiguous intervening normal artery), with possible extension into the popliteal artery distal to the center of the knee joint space (the P3 segment)

Read More

Exclusion Criteria

Screening Criteria:

• Patient unwilling or unlikely to comply with visit schedule
• Planned major index limb amputation
• Active foot infection; however, osteomyelitis in the toes or mild cellulitis around the perimeter of gangrene or small ulcers are not exclusions, but osteomyelitis of the metatarsal or more proximal region would be exclusionary
• Inability to receive study medications
• Estimated glomerular filtration rate (eGFR) less than 30 mL/min, except for patients with end stage renal disease on chronic hemodialysis
• Stage 3 (per SVS WIfI classification) or worse heel ulcers or heel ulcers that are determined to be primarily neuropathic in nature

Angiographic/Procedural Criteria:

• Hemodynamically significant inflow lesion (≥50% DS) or occlusion in the ipsilateral iliac, SFA, or popliteal arteries in which there is a failure to successfully treat and obtain a <30% residual stenosis
• Index lesion length is >30 cm as measured from proximal normal vessel to distal normal vessel
• Total length of lesions treated during the case (including target lesion, inflow lesions, and other non-index lesions) >50 cm
• Lesions revascularized during the index case but untreated by Bullfrog
• Use of alternative therapy, e.g. atherectomy, laser, or radiation therapy, as part of the index lesion treatment, or use of any drug eluting stents (DES) or drug-eluting balloon/drug-coated balloons (DEB/DCB) for treatment of any infra-inguinal lesions during the study procedure or during the initial six-month follow up period
• Previously implanted stent in the TL(s)
• Aneurysm in the target vessel
• Acute thrombus in the target limb
• Failure to cross the TL with a guide wire; however, subintimal wire crossing is allowed
• Heavy eccentric or concentric calcification at index lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion Device needle through the vessel wall

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment Group: Dexamethasone Delivery	Dexamethasone sodium phosphate injection, USP, 4 mg/mL	Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States. Patients will be randomized 1:1 to receive either the active treatment or control therapy. Treatment Group: Standard endovascular revascularization therapy consisting of angioplasty followed by Dexamethasondihydrogenphosphat-dinatrium (Ph.Eur.) 4 mg/mL Injektionslösung and with or without stent placement. The drug is diluted to 3.2 mg/mL and administered to the adventitia per Bullfrog Instructions for Use in a dose of 0.8 mg dexamethasone (0.25 mL) per cm of desired vessel treatment length, up to 30 cm.

Primary Outcome Measures

Name	Time	Method
Composite clinical safety by freedom from adverse events including death, MALE, major unplanned amputation, or CD-TLR.	Up to 6 months following the procedure	Freedom from composite of death within 30 days from the index procedure, MALE, major unplanned amputation or CD-TLR within 6 months.
Freedom from MALE	Up to 6 months following the procedure	Freedom from major adverse limb event (MALE) within 6 months.
Freedom from CD-TLR	Up to 6 months following the procedure	Freedom from clinically driven target lesion revascularization (CD-TLR) within 6 months.
TVAL% change from post-procedure	6 months following the procedure	Transverse-view vessel area loss percentage (TVAL%) of the target lesion at 6 months by quantitative vascular angiography (QVA) or prior to any CD-TLR of the target lesion before 6 months.

Secondary Outcome Measures

Name	Time	Method
Change in foot wounds versus baseline	30 days, 6 and 12 months post-procedure	The number and total size of foot wounds, reduction in number and size of baseline wounds, and occurrence of new wounds (number and size) will be measured against baseline.
Secondary sustained clinical improvement versus baseline	30 days, 6 and 12 months post-procedure	Sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.
Walking capacity assessment versus baseline	30 days, 6 and 12 months post-procedure
Composite clinical safety by freedom from adverse events including death, unplanned amputation, CD-TLR, SAE or MALE.	Up to 12 months following the procedure	Freedom from composite of death, unplanned amputation and CD-TLR, serious adverse events (SAE) and MALE.
QVA change from post-procedure	6 months following the procedure	Improvement in % diameter stenosis (%DSS) of the target lesion (TL) and the maximum late lumen loss for the lesion (LLL) will be assessed by quantitative vascular angiography (QVA).
IVUS change from post-procedure	6 months following the procedure	Improvement in intravascular ultrasound (IVUS) result with in the TL (subgroup analysis).
EQ5D versus baseline	30 days, 6 and 12 months post-procedure	Quality of life assessment.
CD-TLR	30 days, 6 and 12 months post-procedure
SAE/MALE assessment	30 days, 6 and 12 months post-procedure
Infusion technical success	Intra-procedural	The grade of distribution (A-F) around infusion sites will be used as a qualitative measure of technical success of adventitial delivery of the drug.
Event-free survival	12 months following the procedure	Proportion of patients reaching 12-month endpoint without a composite clinical safety event.
Amputation-free survival	30 days, 6 and 12 months post-procedure	Percentage of patients reaching the endpoints without major or minor amputation.
Major and minor amputations and amputation level	30 days, 6 and 12 months post-procedure	Percentage of patients requiring amputation (major: above ankle, minor: below ankle), categorized by level on the foot, ankle, or leg.
Resolved CLI death	30 days, 6 and 12 months post-procedure	The rate of deaths in patients who had a resolution of their critical limb ischemia (CLI).
Primary sustained clinical improvement versus baseline	30 days, 6 and 12 months post-procedure	Sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.
SVS WIfI score versus baseline	30 days, 6 and 12 months post-procedure
Inflammatory biomarker changes from baseline	24 hours and 30 days
Revascularization success	Intra-procedural	Establishment of antegrade flow with residual stenosis \<30% by angiogram.
Healthcare economic analysis	From baseline to 24 months	An analysis of the economics associated with the care of patients, including number of hospital days throughout the study, return visits and hospitalizations, time from index procedure to required revascularization and number of index-lesion-related readmissions.

Trial Locations

Locations (3)

Universitätsklinikum Leipzig AöR; 🇩🇪 Leipzig, Germany

Universitäts-Herzzentrum Freiburg Bad Krozingen GmbH; 🇩🇪 Bad Krozingen, Germany

Medinos Kliniken des Landkreiss Sonneberg GmbH; 🇩🇪 Sonneberg, Germany